Clinical Trials Logo

Filter by:
NCT ID: NCT06093854 Not yet recruiting - Spinal Metastases Clinical Trials

Intraoperative Radiotherapy in Treating Spinal Metastases

Start date: January 2024
Phase: N/A
Study type: Interventional

In order to provide theoretical evidence for the comprehensive and standardized treatment of spinal metastases with pathological fractures and/or spinal cord compression, the investigators conduct this trial to investigate the efficacy and safety of IORT and postoperative SBRT in adjuvant treatment of metastatic spinal tumors after posterior decompression surgery by recruiting patients with spinal metastases who met the inclusion criteria, and randomly divided them into the following treatment cohorts: 1) decompression surgery + IORT (15-20 Gy, 20-50min); 2) decompression surgery and postoperative SBRT(30Gy, 5 fractions, 3 weeks).

NCT ID: NCT06093841 Not yet recruiting - Clinical trials for Lymphoma, Large B-Cell, Diffuse

Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL

Start date: November 2023
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to asess the efficacy of Relmacabtagene autoleucel as second-line therapy in adult patients with aggressive B-cell Non-Hodgkins Lymphoma who are ineligible for haematopoietic stem cell transplantation.

NCT ID: NCT06092762 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Phase II Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Start date: November 6, 2023
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, open label phase II clinical study to evaluate the safety and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.

NCT ID: NCT06092684 Not yet recruiting - Laparoscopy Clinical Trials

The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery

Start date: October 2023
Phase: Phase 3
Study type: Interventional

The objective is to evaluate the efficacy and safety of BT-KTM-I(Esketamine Hydrochloride Injection produced by Chengdu Brilliant Pharmaceutical Co., Ltd.) for general anesthesia, using the Originator drug Ketanest®S(Esketamine Hydrochloride Injection) as a positive control.

NCT ID: NCT06092671 Not yet recruiting - Anesthesia Clinical Trials

Effect of Family-centered Perioperative Care for Anesthesia (FPCA) on Incidence of Emergency Delirium and Postoperative Maladaptive Behaviors in Children After Surgery

Start date: October 2023
Phase: N/A
Study type: Interventional

Emergency delirium (ED) is one of the most common postoperative complications in pediatric patients and is associated with an increase of hospitalization time, healthcare costs, and increased incidence of postoperative maladaptive behaviors (POMBs). There is no clear pharmacological or non-pharmacological interventions that are effective in reducing the incidence of ED or POMBs. Therefore, the investigators aimed to assess whether family-centered perioperative care for anesthesia (FPCA) reduce the incidence of ED or POMBs in children compared with conventional preoperative pharmacological interventions.

NCT ID: NCT06092242 Not yet recruiting - Colorectal Cancer Clinical Trials

The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

Start date: October 15, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of TAS-102 combined with bevacizumab as first-line therapy in patients with advanced colorectal cancer who could not tolerate or did not receive combined chemotherapy

NCT ID: NCT06092047 Not yet recruiting - Clinical trials for CD19-positive Relapsed or Refractory B-cell Malignancies

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

Start date: October 2023
Phase: Early Phase 1
Study type: Interventional

This study is designed for exploring the preliminary safety and efficacy of the recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell hematolymphatic malignancies.

NCT ID: NCT06091332 Not yet recruiting - Clinical trials for Brain Stem Hemorrhage

Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: a Single Centre, Randomised, Placebo-controlled Trial

CALM
Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

This study employs a single-center, prospective, randomized controlled, double-blind exploratory research design. To investigate whether Sirolimus can reduce the rebleeding rate of brainstem cavernous malformations within 24 months after the first symptomatic bleeding event.

NCT ID: NCT06090994 Not yet recruiting - Colorectal Cancer Clinical Trials

Prevention of Postoperative Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Standard Treatment

Start date: October 2023
Phase: Phase 4
Study type: Interventional

This study is a prospective, multicenter, and exploratory study aimed at evaluating the effectiveness of Huaier Granules in preventing postoperative recurrence and metastasis of colorectal cancer.

NCT ID: NCT06090890 Not yet recruiting - In-stent Restenosis Clinical Trials

Anti-inflammatory Therapy for Recurrent In-stent Restenosis

Start date: October 30, 2023
Phase: Phase 4
Study type: Interventional

This study is aimed at making a comparison of the safety and efficacy of standard drug therapy (control group), standard drugs combined with lose-dose colchicine therapy (colchicine group) and standard drug combined with prednisone therapy (prednisone group) in patients with coronary heart disease who suffered from recurrent In-stent restenosis (RISR).